Search

Displaying results 2381 - 2390 of 6951 in total
  1. Drug

    Gramicidin D

    go.drugbank.com/drugs/DB00027
    ApprovedInvestigational

    Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus brevis and called collectively grami...

    Mixtures: Polysporin for Kids, Antibiotic Cream for Kids
  2. Drug

    Meningococcal polysaccharide vaccine group A

    go.drugbank.com/drugs/DB13889
    ApprovedInvestigational

    Meningococcal group A polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup A. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis a...

    Mixtures: MENVEO POWDER & SOLUTION FOR SOLUTION FOR INJECTION, Menveo Powder and Solution for Solution for Injection
  3. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension.

    Categories: Imidazoline Receptor Agonists, Adrenergic alpha-2 Receptor Agonists
  4. Drug

    Meningococcal polysaccharide vaccine group C

    go.drugbank.com/drugs/DB13890
    ApprovedInvestigational

    Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup C. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis a...

    Mixtures: MENVEO POWDER & SOLUTION FOR SOLUTION FOR INJECTION, Menveo Powder and Solution for Solution for Injection
  5. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … Concizumab therefore provides an important treatment option for patients who have developed inhibitors to standard clotting factor replacement therapy.

  6. Drug

    Arbutin

    go.drugbank.com/drugs/DB11217
    Approved

    It has also been used as an anti-infective for the urinary system as well as a diuretic [F43]. … Most commonly, it is an active ingredient in skincare and cosmetic products as a skin-lightening agent for the prevention of melanin formation in various skin conditions that involve cutaneous hyperpigmentation

  7. Drug

    Iodoform

    go.drugbank.com/drugs/DB13813
    ApprovedInvestigationalVet approvedWithdrawn

    Due to its antimicrobial properties following topical administration, minimal levels of iodoform may be found in disinfectants and it is more primarily used for veterinary purposes. … Since the beginning of the 20th century, iodoform has been commonly used as a healing and antiseptic dressing or powder for wounds and sores, however such clinical use to this date is limited.

  8. Drug

    Becaplermin

    go.drugbank.com/drugs/DB00102
    ApprovedInvestigational

    Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae.

    Categories: Preparations for Treatment of Wounds and Ulcers
  9. Drug

    Phenylbutazone

    go.drugbank.com/drugs/DB00812
    ApprovedVet approvedWithdrawn

    Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)

    Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical Use
  10. Drug

    Rofecoxib

    go.drugbank.com/drugs/DB00533
    ApprovedWithdrawn

    Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras.